MCID: ERY066
MIFTS: 29

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme Major

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 58 6 70
Erythema Exsudativum Multiforme Majus 58
Erythema Multiforme Majus 58
Stevens-Johnson Syndrome 70

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Orphanet 58 ORPHA502499
UMLS 70 C0038325 C3241919

Summaries for Erythema Multiforme Major

MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. An important gene associated with Erythema Multiforme Major is HLA-B (Major Histocompatibility Complex, Class I, B). The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and t cells.

Related Diseases for Erythema Multiforme Major

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major

Symptoms & Phenotypes for Erythema Multiforme Major

Drugs & Therapeutics for Erythema Multiforme Major

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Molgramostim Investigational Phase 4 99283-10-0
4 Anti-Infective Agents Phase 4
5 Ophthalmic Solutions Phase 4
6 Immunosuppressive Agents Phase 4
7 Calcineurin Inhibitors Phase 4
8 Antifungal Agents Phase 4
9
Etanercept Approved, Investigational Phase 3 185243-69-0
10
Coal tar Approved Phase 3 8007-45-2
11
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
12
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
13 Immunologic Factors Phase 2, Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 3
15 Analgesics Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Pharmaceutical Solutions Phase 2, Phase 3
18 Adjuvants, Immunologic Phase 2, Phase 3
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
20
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
21 Micronutrients Phase 1, Phase 2
22 Trace Elements Phase 1, Phase 2
23 Nutrients Phase 1, Phase 2
24 Vitamin B9 Phase 1, Phase 2
25 Vitamin B Complex Phase 1, Phase 2
26 Folate Phase 1, Phase 2
27 Photosensitizing Agents Phase 1, Phase 2
28 Vitamins Phase 1, Phase 2
29 Vitamin B2 Phase 1, Phase 2
30
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
31
tannic acid Approved Phase 1 1401-55-4
32 Anesthetics Phase 1
33 Anesthetics, Local Phase 1
34
Allopurinol Approved 315-30-0 2094
35
Isotretinoin Approved 4759-48-2 5538 5282379
36 Anti-Bacterial Agents
37 Immunoglobulin A
38 Immunoglobulins
39 Rho(D) Immune Globulin
40 Immunoglobulins, Intravenous
41 gamma-Globulins
42 Antibodies
43 Cyclosporins

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
3 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
4 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
5 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
6 Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Not yet recruiting NCT04651439 Phase 2, Phase 3 Filgrastim;Placebo
7 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
8 Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial Not yet recruiting NCT04711200 Phase 1, Phase 2 Adipose derived stromal cells intravenously injected
9 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
10 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
11 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
12 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
13 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
14 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Completed NCT03878771 Phase 1 Dermovate cream in Orabase
15 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
16 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
17 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Unknown status NCT02574988
18 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
19 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
20 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
21 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
22 An Evaluation of Tangible Boost Replenishing System for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Versus Host Disease Recruiting NCT04313725
23 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
24 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
25 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
26 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
27 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison

Search NIH Clinical Center for Erythema Multiforme Major

Genetic Tests for Erythema Multiforme Major

Anatomical Context for Erythema Multiforme Major

MalaCards organs/tissues related to Erythema Multiforme Major:

40
Eye, Salivary Gland, T Cells, Skin, Liver, Endothelial, Thymus

Publications for Erythema Multiforme Major

Articles related to Erythema Multiforme Major:

(show top 50) (show all 3747)
# Title Authors PMID Year
1
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. 6 61
23588310 2013
2
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 6 61
21428768 2011
3
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 61 6
16538176 2006
4
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 61 6
15743917 2005
5
Medical genetics: a marker for Stevens-Johnson syndrome. 61 6
15057820 2004
6
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. 6 61
8006430 1994
7
Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. 61
33279401 2021
8
Mucous membrane grafting for lid margin keratinization in Stevens Johnson syndrome - An eye opening saga. 61
33727433 2021
9
Lacrimal Gland Involvement in Severe Dry Eyes after Stevens-Johnson Syndrome. 61
32835747 2021
10
Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33055536 2021
11
SkinSerious: Disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
33515629 2021
12
A beginner's guide to mucous membrane grafting for lid margin keratinization: Review of indications, surgical technique and clinical outcomes. 61
33727438 2021
13
Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality. 61
32991765 2021
14
Patients', family members' and healthcare practitioners' experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis: a qualitative descriptive study using emotional touchpoints. 61
32977354 2021
15
Corneal ectasia with Stevens-Johnson syndrome. 61
33689647 2021
16
Management of Stevens-Johnson syndrome using a mini-scleral contact lens. 61
33107055 2021
17
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. 61
33657677 2021
18
Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. 61
32289398 2021
19
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. 61
32561372 2021
20
Evaluation of drug patch tests in children. 61
33685563 2021
21
Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. 61
32920914 2021
22
Cohort study of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography. 61
33644844 2021
23
Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. 61
33474859 2021
24
Ciprofloxacin-induced cutaneous adverse drug events: a systematic review of descriptive studies. 61
33725760 2021
25
[Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis]. 61
33725172 2021
26
Diphtheroids as Corneal Pathogens in Chronic Ocular Surface Disease in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33758140 2021
27
Direct Injection of 5-Fluorouracil Improves Outcomes in Cicatrizing Conjunctival Disorders Secondary to Systemic Disease. 61
32427724 2021
28
Detecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte-Mediated Bullous Skin Disorders. 61
33039642 2021
29
Levamisole induced toxic epidermal necrolysis: A case report. 61
32851655 2021
30
In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database. 61
33417306 2021
31
MEEI special issue Fellows' PaperStevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors. 61
33764253 2021
32
The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. 61
32896010 2021
33
Interdisciplinary Safety Evaluation for Learning and Decision-Making. 61
33730364 2021
34
Blistering severe cutaneous adverse reactions in children: Proposal for pediatric-focused clinical criteria. 61
33730370 2021
35
Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children's hospital in Japan: A retrospective observational cohort study. 61
33740697 2021
36
Toxic Epidermal Necrolysis Like Lupus - A Case Series. 61
33760256 2021
37
Rash and Mucositis Associated With Mycoplasma pneumoniae and Chlamydophila pneumoniae: A Recurrence of MIRM? 61
32275058 2021
38
Amniotic membrane transplantation in a 2-month-old infant with toxic epidermal necrolysis. 61
33521381 2021
39
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). 61
32846030 2021
40
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). 61
33650659 2021
41
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes. 61
33673164 2021
42
Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrolysis in the UK population. 61
33536518 2021
43
Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population. 61
33217035 2021
44
Porphyria cutanea tarda exacerbation as a paraneoplastic syndrome in vaginal cancer resolved with chemoradiation. 61
33426257 2021
45
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. 61
33635229 2021
46
Human leukocyte antigen class I and II genes associated with dipyrone-related Stevens-Johnson syndrome and severe ocular complications in a Brazilian population. 61
33617977 2021
47
Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
33332598 2021
48
Mapping of susceptible variants for cold medicine-related Stevens-Johnson syndrome by whole-genome resequencing. 61
33574277 2021
49
A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
33631950 2021
50
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case-control and cohort studies. 61
33618992 2021

Variations for Erythema Multiforme Major

ClinVar genetic disease variations for Erythema Multiforme Major:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-B HLA-B*15:02 Variation risk factor 14909 GRCh37:
GRCh38:
2 HLA-B HLA-B, HLA-B*5801 Variation risk factor 14911 GRCh37:
GRCh38:

Expression for Erythema Multiforme Major

Search GEO for disease gene expression data for Erythema Multiforme Major.

Pathways for Erythema Multiforme Major

GO Terms for Erythema Multiforme Major

Sources for Erythema Multiforme Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....